Shopping Cart 0
Cart Subtotal
USD 0

Hypercholesterolemia-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Hypercholesterolemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia-Pipeline Review, H1 2017, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 14, 3, 1, 1, 20, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Hypercholesterolemia-Overview 6

Hypercholesterolemia-Therapeutics Development 7

Hypercholesterolemia-Therapeutics Assessment 18

Hypercholesterolemia-Companies Involved in Therapeutics Development 28

Hypercholesterolemia-Drug Profiles 47

Hypercholesterolemia-Dormant Projects 170

Hypercholesterolemia-Discontinued Products 174

Hypercholesterolemia-Product Development Milestones 175

Appendix 189


List Of Figure

List of Figures

Number of Products under Development for Hypercholesterolemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Hypercholesterolemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hypercholesterolemia-Pipeline by 3SBio Inc, H1 2017

Hypercholesterolemia-Pipeline by AFFiRiS AG, H1 2017

Hypercholesterolemia-Pipeline by Akcea Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Alvogen Korea Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by ARMO Biosciences Inc, H1 2017

Hypercholesterolemia-Pipeline by AstraZeneca Plc, H1 2017

Hypercholesterolemia-Pipeline by BioLingus AG, H1 2017

Hypercholesterolemia-Pipeline by Catabasis Pharmaceuticals Inc, H1 2017

Hypercholesterolemia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Hypercholesterolemia-Pipeline by CymaBay Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Daewon Pharm Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Daewoong Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Dicerna Pharmaceuticals Inc, H1 2017

Hypercholesterolemia-Pipeline by Dybly AG, H1 2017

Hypercholesterolemia-Pipeline by Esperion Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Gemphire Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Golden Biotechnology Corp, H1 2017

Hypercholesterolemia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Immune Response BioPharma Inc, H1 2017

Hypercholesterolemia-Pipeline by Johnson & Johnson, H1 2017

Hypercholesterolemia-Pipeline by Kadmon Corp LLC, H1 2017

Hypercholesterolemia-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Leading BioSciences Inc, H1 2017

Hypercholesterolemia-Pipeline by LipimetiX Development Inc, H1 2017

Hypercholesterolemia-Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Medlab Clinical Ltd, H1 2017

Hypercholesterolemia-Pipeline by Merck & Co Inc, H1 2017

Hypercholesterolemia-Pipeline by Pfizer Inc, H1 2017

Hypercholesterolemia-Pipeline by Planet Biotechnology Inc, H1 2017

Hypercholesterolemia-Pipeline by Progenra Inc, H1 2017

Hypercholesterolemia-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Hypercholesterolemia-Pipeline by RegenxBio Inc, H1 2017

Hypercholesterolemia-Pipeline by Serometrix LLC, H1 2017

Hypercholesterolemia-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Solvotrin Therapeutics Ltd, H1 2017

Hypercholesterolemia-Pipeline by The Medicines Company, H1 2017

Hypercholesterolemia-Pipeline by Viking Therapeutics Inc, H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017 (Contd..2), H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017 (Contd..3), H1 2017

Hypercholesterolemia-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

3SBio Inc, AFFiRiS AG, Akcea Therapeutics Inc, Alvogen Korea Co Ltd, ARMO Biosciences Inc, AstraZeneca Plc, BioLingus AG, Catabasis Pharmaceuticals Inc, Chong Kun Dang Pharmaceutical Corp, CymaBay Therapeutics Inc, Daewon Pharm Co Ltd, Daewoong Co Ltd, Dicerna Pharmaceuticals Inc, Dybly AG, Esperion Therapeutics Inc, Gemphire Therapeutics Inc, Golden Biotechnology Corp, Hanmi Pharmaceuticals Co Ltd, Immune Response BioPharma Inc, Johnson & Johnson, Kadmon Corp LLC, Kyorin Pharmaceutical Co Ltd, Leading BioSciences Inc, LipimetiX Development Inc, Lotus Pharmaceutical Co Ltd, Medlab Clinical Ltd, Merck & Co Inc, Pfizer Inc, Planet Biotechnology Inc, Progenra Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, Serometrix LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Solvotrin Therapeutics Ltd, The Medicines Company, Viking Therapeutics Inc

Company Profile

Company Profile Title

Hypercholesterolemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia-Pipeline Review, H1 2017, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 14, 3, 1, 1, 20, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Hypercholesterolemia-Overview 6

Hypercholesterolemia-Therapeutics Development 7

Hypercholesterolemia-Therapeutics Assessment 18

Hypercholesterolemia-Companies Involved in Therapeutics Development 28

Hypercholesterolemia-Drug Profiles 47

Hypercholesterolemia-Dormant Projects 170

Hypercholesterolemia-Discontinued Products 174

Hypercholesterolemia-Product Development Milestones 175

Appendix 189


List Of Figure

List of Figures

Number of Products under Development for Hypercholesterolemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Hypercholesterolemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hypercholesterolemia-Pipeline by 3SBio Inc, H1 2017

Hypercholesterolemia-Pipeline by AFFiRiS AG, H1 2017

Hypercholesterolemia-Pipeline by Akcea Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Alvogen Korea Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by ARMO Biosciences Inc, H1 2017

Hypercholesterolemia-Pipeline by AstraZeneca Plc, H1 2017

Hypercholesterolemia-Pipeline by BioLingus AG, H1 2017

Hypercholesterolemia-Pipeline by Catabasis Pharmaceuticals Inc, H1 2017

Hypercholesterolemia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Hypercholesterolemia-Pipeline by CymaBay Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Daewon Pharm Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Daewoong Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Dicerna Pharmaceuticals Inc, H1 2017

Hypercholesterolemia-Pipeline by Dybly AG, H1 2017

Hypercholesterolemia-Pipeline by Esperion Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Gemphire Therapeutics Inc, H1 2017

Hypercholesterolemia-Pipeline by Golden Biotechnology Corp, H1 2017

Hypercholesterolemia-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Immune Response BioPharma Inc, H1 2017

Hypercholesterolemia-Pipeline by Johnson & Johnson, H1 2017

Hypercholesterolemia-Pipeline by Kadmon Corp LLC, H1 2017

Hypercholesterolemia-Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Leading BioSciences Inc, H1 2017

Hypercholesterolemia-Pipeline by LipimetiX Development Inc, H1 2017

Hypercholesterolemia-Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Medlab Clinical Ltd, H1 2017

Hypercholesterolemia-Pipeline by Merck & Co Inc, H1 2017

Hypercholesterolemia-Pipeline by Pfizer Inc, H1 2017

Hypercholesterolemia-Pipeline by Planet Biotechnology Inc, H1 2017

Hypercholesterolemia-Pipeline by Progenra Inc, H1 2017

Hypercholesterolemia-Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Hypercholesterolemia-Pipeline by RegenxBio Inc, H1 2017

Hypercholesterolemia-Pipeline by Serometrix LLC, H1 2017

Hypercholesterolemia-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017

Hypercholesterolemia-Pipeline by Solvotrin Therapeutics Ltd, H1 2017

Hypercholesterolemia-Pipeline by The Medicines Company, H1 2017

Hypercholesterolemia-Pipeline by Viking Therapeutics Inc, H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017 (Contd..1), H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017 (Contd..2), H1 2017

Hypercholesterolemia-Dormant Projects, H1 2017 (Contd..3), H1 2017

Hypercholesterolemia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

3SBio Inc, AFFiRiS AG, Akcea Therapeutics Inc, Alvogen Korea Co Ltd, ARMO Biosciences Inc, AstraZeneca Plc, BioLingus AG, Catabasis Pharmaceuticals Inc, Chong Kun Dang Pharmaceutical Corp, CymaBay Therapeutics Inc, Daewon Pharm Co Ltd, Daewoong Co Ltd, Dicerna Pharmaceuticals Inc, Dybly AG, Esperion Therapeutics Inc, Gemphire Therapeutics Inc, Golden Biotechnology Corp, Hanmi Pharmaceuticals Co Ltd, Immune Response BioPharma Inc, Johnson & Johnson, Kadmon Corp LLC, Kyorin Pharmaceutical Co Ltd, Leading BioSciences Inc, LipimetiX Development Inc, Lotus Pharmaceutical Co Ltd, Medlab Clinical Ltd, Merck & Co Inc, Pfizer Inc, Planet Biotechnology Inc, Progenra Inc, Regeneron Pharmaceuticals Inc, RegenxBio Inc, Serometrix LLC, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Solvotrin Therapeutics Ltd, The Medicines Company, Viking Therapeutics Inc